Medicare, Medicaid, and CLIA Programs; Clinical Laboratory Improvement Amendments of 1988; Continuance of Exemption of Laboratories Licensed by the State of Washington, 22317-22320 [05-8286]
Download as PDF
Federal Register / Vol. 70, No. 82 / Friday, April 29, 2005 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10117, 10118,
10119, 10135, 10136 and CMS–R–138]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, HHS.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare & Medicaid
Services (CMS) is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
1. Type of Information Collection
Request: Extension of a currently
approved collection; Title of
Information Collection: Medicare
Advantage Application for Coordinated
Care, Private Fee-for-Service, Regional
Preferred Provider Organization, Service
Area Expansion for Coordinated Care
and Private Fee-for-Service Plans,
Medical Savings Account Plans; Form
Nos.: CMS–10117, 10118, 10119, 10135,
10136 (OMB # 0938–0935); Use: Health
plans must meet certain regulatory
requirements to enter into a contract
with CMS to provide health benefits to
Medicare beneficiaries. These
applications are the collection forms to
obtain the information from a health
plan that will allow CMS staff to
determine compliance with the
regulations; Frequency: Other—one-time
submission; Affected Public: Business or
other for-profit, Not-for-profit
institutions, and State, Local or Tribal
Government; Number of Respondents:
420; Total Annual Responses: 520; Total
Annual Hours: 20,100.
2. Type of Information Collection
Request: Extension of a currently
approved collection; Title of
Information Collection: Medicare
Geographic Classification Review Board
AGENCY:
VerDate jul<14>2003
16:04 Apr 28, 2005
Jkt 205001
(MGCRB) Procedures and Supporting
Regulations in 42 CFR Sections 412.256
and 412.230; Form Nos.: CMS–R–138
(OMB #0938–0573); Use: Section
1886(d)(10) of the Social Security Act
established the Medicare Geographic
Classification Review Board (MGCRB),
an entity with the authority to accept
short-term hospital inpatient
prospective payment system
applications from hospitals requesting
geographic reclassification for wage
index or standardized payment amounts
and to issue decisions on these requests.
This regulation sets up the application
process for prospective payment system
hospitals that choose to appeal their
geographic status to the MGCRB. This
regulation also establishes procedural
guidelines for the MGCRB; Frequency:
Reporting—Annually; Affected Public:
Business or other for-profit, Not-forprofit institutions; Number of
Respondents: 500; Total Annual
Responses: 500; Total Annual Hours:
500.
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS’ Web site
address at https://www.cms.hhs.gov/
regulations/pra/, or e-mail your request,
including your address, phone number,
OMB number, and CMS document
identifier, to Paperwork@cms.hhs.gov,
or call the Reports Clearance Office on
(410) 786–1326.
Written comments and
recommendations for the proposed
information collections must be mailed
within 60 days of this notice to the
address below:CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations
Development,Attention: Melissa
Musotto, PRA Specialist,Room C4–26–
05,7500 Security Boulevard,Baltimore,
Maryland 21244–1850.
Dated: April 22, 2005.
Michelle Shortt,
Acting Director, Regulations Development
Group, Office of Strategic Operations and
Regulatory Affairs.
[FR Doc. 05–8713 Filed 4–28–05; 8:45 am]
BILLING CODE 4120–01–P
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
22317
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–2207–N]
Medicare, Medicaid, and CLIA
Programs; Clinical Laboratory
Improvement Amendments of 1988;
Continuance of Exemption of
Laboratories Licensed by the State of
Washington
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This notice announces that
laboratories located in the State of
Washington that possess a valid license
under the Medical Test Site Licensure
Law, Chapter 70.42 of the Revised Code
of Washington (RCW), continue to be
exempt from the requirements of the
Clinical Laboratory Improvement
Amendments of 1988 (CLIA) until April
30, 2007.
DATES: The continuance granted by this
notice is effective until April 30, 2007.
FOR FURTHER INFORMATION CONTACT:
Sandra Farragut, (410) 786–3531.
SUPPLEMENTARY INFORMATION:
I. Background
Section 353 of the Public Health
Service Act (PHS Act), as amended by
the Clinical Laboratory Improvement
Amendments of 1988, Pub. L. 100–578
(CLIA), provides that no laboratory may
perform tests on human specimens
unless it has a certificate to perform
these tests issued by the Secretary of the
Department of Health and Human
Services (HHS). Under section 1861(s)
of the Social Security Act, the Medicare
program will pay for laboratory services
only if the laboratory has a CLIA
certificate. Section 1902(a)(9)(C) of the
Social Security Act requires that State
Medicaid plans pay only for laboratory
services furnished by CLIA-certified
laboratories. Thus, although subject to
specified exemptions, laboratories
generally must have a current and valid
CLIA certificate to test human
specimens and to be eligible for
payment from the Medicare or Medicaid
programs. Regulations implementing
section 353 of the PHS Act are
contained in 42 CFR part 493.
Section 353(p) of the PHS Act
provides for the exemption of
laboratories from CLIA requirements in
a State that applies requirements that
are equal to or more stringent than those
of CLIA.
Regulations in 42 CFR part 493
subpart E implement section 353(p) of
E:\FR\FM\29APN1.SGM
29APN1
22318
Federal Register / Vol. 70, No. 82 / Friday, April 29, 2005 / Notices
the PHS Act. Sections 493.551 and
493.553 provide that we may exempt
from CLIA requirements, for a period
not to exceed 6 years, all State licensed
or approved laboratories in a State if the
State Licensure Program meets specified
conditions. Section 493.559 provides
that we will publish a notice in the
Federal Register when we grant
exemption to a State Laboratory
licensure program. It also provides that
the notice will include the following:
the basis for granting the exemption, a
description of how the laboratory
requirements are equal to or more
stringent than those of CLIA, and the
term of approval, not to exceed 6 years.
On July 1, 1997 (62 FR 35513), we
published a notice in the Federal
Register announcing that the State of
Washington had applied for exemption
of its laboratories from CLIA
requirements; that the evaluation of this
application demonstrated that all
requirements for exemption were met;
and that the Washington State
Laboratory licensure program was
granted an approval of CLIA exemption
for laboratories in its program.
II. Requirements for Granting CLIA
Exemption
In order to determine whether we
should grant or continue an approval of
an existing CLIA exemption to
laboratories licensed by a State, we
conduct a detailed and in-depth
comparison of State licensure program
and CLIA requirements to determine
whether the State program meets the
requirements at § 493.551 and § 493.553.
In summary, the State must—
• Have laws in effect that provide for
requirements that are equal to or more
stringent than CLIA requirements;
• Have a State licensure program that
licenses or approves laboratories that
meet State requirements that meet or
exceed CLIA requirements, and,
therefore, meet the condition-level
requirements of the CLIA regulations;
• Meet the requirements and be
approved in accordance with § 493.555
and § 493.557(b);
• Demonstrate that it has enforcement
authority and administrative structures
and resources adequate to enforce its
laboratory requirements;
• Permit CMS or CMS agents to
inspect laboratories within the State;
• Require laboratories within the
State to submit to inspections by CMS
or CMS agents as a condition of
licensure;
• Agree to pay the cost of the
validation program administered by
CMS and the cost of the State’s pro rata
share of the general overhead to develop
and implement CLIA as specified in
VerDate jul<14>2003
16:04 Apr 28, 2005
Jkt 205001
§ 493.645(a), § 493.646(b), and
§ 493.557(b); and
• Take appropriate enforcement
action against laboratories found by
CMS or CMS agents not to be in
compliance with requirements
comparable to condition-level
requirements, as specified in
§ 493.557(b).
As specified in our regulations at
§ 493.555 and § 493.557(b), our review
of a State laboratory program includes
(but is not necessarily limited to) an
evaluation of—
• Whether the State’s requirements
for laboratories are equal to or more
stringent than the CLIA condition-level
requirements;
• The State’s inspection process
requirements to determine—
—The comparability of the full
inspection and complaint inspection
procedures to those of CMS;
—The State’s enforcement procedures
for laboratories found to be out of
compliance with its requirements;
and
—The ability of the State to provide
CMS with electronic data and reports
with the adverse or corrective actions
resulting from proficiency testing (PT)
results that constitute unsuccessful
participation in CMS-approved PT
programs and with other data we
determine to be necessary for
validation review and assessment of
the State’s inspection process
requirements;
• The State’s agreement with us to
ensure that the agreement obligates the
State to—
—Notify CMS within 30 days of the
action taken against any CLIA-exempt
laboratory that has had its licensure or
approval withdrawn or revoked or
been in any way sanctioned;
—Notify CMS within 10 days of any
deficiency identified in a CLIAexempt laboratory in cases when the
deficiency poses an immediate
jeopardy to the laboratory’s patients
or a hazard to the general public;
—Notify each laboratory licensed by the
State within 10 days of CMS’
withdrawal of the exemption;
—Provide CMS with written notification
of any changes in its licensure (or
approval) and inspection
requirements;
—Disclose to CMS or a CMS agent any
laboratory’s PT results in accordance
with a State’s confidentiality
requirements;
—Take the appropriate enforcement
action against laboratories found by
CMS not to be in compliance with
requirements comparable to CLIA
condition-level requirements and
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
report these enforcement actions to
CMS;
—Notify CMS of all newly licensed
laboratories, including changes in the
specialties and subspecialties for
which any laboratory performs
testing, within 30 days; and
—Provide CMS, as requested, inspection
schedules for validation purposes.
III. Evaluation of Washington’s Request
for Continued CLIA Exemption of Its
Laboratories
Washington has applied for continued
exemption of its laboratories from CLIA
program requirements.
We evaluated the application to verify
Washington’s assurance of continued
compliance with the following subparts
of part 493: Subpart H, Participation in
Proficiency Testing for Laboratories
Performing Nonwaived Testing; Subpart
J, Facility Administration for
Nonwaived Testing; Subpart K, Quality
Systems for Nonwaived Testing,
Subpart M, Personnel for Nonwaived
Testing; Subpart Q, Inspection; and
Subpart R, Enforcement Procedures.
The Washington State Laboratory
Licensure Program was found to
continue to meet the requirements of
subparts H, J, K, M, Q, and R.
We also verified the State of
Washington’s assurance that it requires
the laboratories it licenses to meet the
requirements for the following subparts
of part 493 as explained below:
Subpart E—Accreditation by a Private,
Nonprofit Accreditation Organization or
Exemption Under an Approved State
Laboratory Program
The State of Washington submitted a
comparison of its laboratory licensure
requirements with comparable CLIA
condition-level requirements (that is, a
crosswalk); a description of its
inspection process; proficiency testing
monitoring process; its data
management and analysis system; its
investigative and complaint response
procedures; its current list of licensed
laboratories; and its policy regarding
announcement and unannouncement of
inspections. We have determined that
the State of Washington has complied
with the requirements under subpart E
of part 493 and that the requirements of
its laboratory licensure program are
equal to the condition-level
requirements in subparts H, J, K, M, Q,
and R of part 493.
Subpart H—Participation in Proficiency
Testing for Laboratories Performing
Nonwaived Testing
The Washington State program’s
requirements are equal to the CLIA
E:\FR\FM\29APN1.SGM
29APN1
Federal Register / Vol. 70, No. 82 / Friday, April 29, 2005 / Notices
The Washington State Laboratory
Licensure Program requires laboratories
to comply with the inspection
requirements of § 493.1773 and
§ 493.1780 of this subpart, as applicable.
Thus, we have determined that the
Washington State Program’s
requirements are equal to the
requirements of the CLIA regulations.
and licensed by the State are in
compliance with CLIA requirements.
Staff in the CMS Regional Office in
Seattle, Washington have conducted
validation inspections of a
representative sample (approximately 5
percent) of the laboratories inspected by
the Washington State Office of
Laboratory Quality Assurance (LQA).
The validation inspections were
primarily of the concurrent type; that is,
CMS surveyors accompanied
Washington’s inspectors, each
inspecting against his or her agency’s
respective regulations. Analysis of the
validation data revealed no significant
differences between the State and
Federal findings. The validation surveys
verified that the Washington inspection
process covers all CLIA conditions
applicable to each laboratory being
inspected, and also verified that the
State laboratory licensure requirements
meet or exceed CLIA condition-level
requirements. The CMS survey staff
found the State inspectors highly skilled
and qualified. The LQA inspected
laboratories in timely fashion, that is, all
laboratories were inspected within the
required 24-month cycle. All parameters
monitored by CMS staff to date indicate
that Washington is meeting all
requirements for approval of CLIA
exemption. This Federal monitoring
will continue as an on-going process.
Approval of the CLIA exemption for
laboratories located in and licensed by
Washington is subject to removal if we
determine that the outcome of a
comparability review or a validation
review inspection is not acceptable, as
described under § 493.573 and
§ 493.575, or if Washington fails to pay
the required fee every 2 years as
required under § 493.646.
Subpart R—Enforcement Procedures
V. Laboratory Data
The Washington State Program meets
the requirements of subpart R to the
extent that subpart R applies to State
laboratory licensure programs.
Accordingly, we have determined that
the Washington State Program’s
enforcement and appeal policies are
equal to the requirements of the CLIA
regulations.
In accordance with § 493.557(b)(8),
Washington will continue to agree to
provide us with changes to a
laboratory’s specialties or subspecialties
based on the State’s survey. Washington
also will provide us with changes in a
laboratory’s certification status, such as
a change from a regular certificate to a
certificate of waiver.
IV. Validation Inspections
VI. Required Administrative Actions
The Federal validation inspections of
CLIA-exempt laboratories, as specified
in § 493.563, were conducted on a
representative sample basis as well as in
response to any substantial allegations
of noncompliance (complaint
inspections). The outcome of those
validation inspections has been and will
continue to be CMS’ principal tool for
verifying that the laboratories located in
CLIA is a totally user-fee funded
program. The registration fee paid by
laboratories is intended to cover the cost
of the development and administration
of the program. However, when a State’s
application for exemption is approved,
we do not charge a fee to laboratories in
the State. The State’s share of the costs
associated with CLIA must be collected
from the State, as specified in § 493.645.
requirements at § 493.801 through
§ 493.865.
Subpart J—Facility Administration for
Nonwaived Testing
The Washington State Program’s
requirements are equal to the CLIA
requirements at § 493.1100 through
§ 493.1105.
Subpart K—Quality System for
Nonwaived Testing
The Quality Control (QC)
requirements of the Washington State
Laboratory Licensure Program have
been evaluated against the requirements
of the CLIA regulations. The
Washington State Program has modified
its survey process and made revisions to
its requirements encompassing general
QC as well as specialty and subspecialty
QC requirements in order to reflect the
new QC requirements of the CLIA
regulations. As such, we have
determined that the Washington State
Program’s requirements are equal to the
requirements of the CLIA regulations.
Subpart M—Personnel for Nonwaived
Testing
The Washington State Program
requirements are equal to the CLIA
requirements at § 493.1403 through
§ 493.1495 for laboratories that perform
moderate and high complexity testing.
Subpart Q—Inspections
VerDate jul<14>2003
16:04 Apr 28, 2005
Jkt 205001
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
22319
Washington must pay for the
following:
• Costs of Federal inspection of
laboratories in the State to verify that
Washington’s laboratory licensure
program requirements are enforced in
an appropriate manner. The average
Federal hourly rate is multiplied by the
total hours required to perform Federal
validation surveys within the State.
• Costs incurred for Federal
investigations and surveys triggered by
complaints that are substantiated. We
will bill Washington on a semiannual
basis.
• Washington’s proportionate share of
the costs associated with establishing,
maintaining, and improving the CLIA
computer system, a portion of those
services from which Washington
received direct benefit or contributed to
the CLIA program in the State. Thus,
Washington is being charged for a
portion of CMS’ direct and indirect
costs as well as a portion of the costs
incurred by the Centers for Disease
Control and Prevention (CDC).
In order to estimate Washington’s
proportionate share of the general
overhead costs to develop and
implement CLIA, we determined the
ratio of laboratories in the State to the
total number of laboratories nationally.
Approximately 1.6 percent of the
registered laboratories are in
Washington. We determined that 1.6
percent of the applicable CDC and CMS
costs should be borne by Washington.
Washington has agreed to pay us the
State’s pro rata share of the overhead
costs and anticipated costs of actual
validation and complaint investigation
surveys. A final reconciliation for all
laboratories and all expenses will be
made. We will reimburse the State for
any overpayment or bill it for any
balance.
VII. Approval
CMS grants continued approval of the
CLIA exemption for all laboratory
specialties and subspecialties to all
laboratories located in and licensed by
the State of Washington effective April
30, 2001 to April 30, 2007.
The State of Washington applied
timely for re-approval, that is, to
continue approval for exemption
beyond the period ending April 30,
2001. Review of the application for
continued approval, and evaluation of
the outcomes of the validation
inspections indicated that continued
approval for 6 more years was in order.
The actual publication of the continued
approval was delayed, however, due to
the timing of the publication of changes
to the CLIA regulations, and
subsequently the time period necessary
E:\FR\FM\29APN1.SGM
29APN1
22320
Federal Register / Vol. 70, No. 82 / Friday, April 29, 2005 / Notices
for the State of Washington to publish
corresponding changes to the
Washington State Medical Test Site
Rules, which were effective March 19,
2005.
VIII. Collection of Information
Requirements
This document does not impose
information collection, and
recordkeeping requirements, which are
subject to the Paperwork Reduction Act
of 1995 (PRA) (44 U.S.C. 35).
Consequently, it need not be reviewed
by the Office of Management and
Budget under the authority of the PRA.
VIX. Regulatory Impact Statement
This notice announces the
continuance of the exemption of
laboratories licensed by the State of
Washington from the requirements of
the Clinical Laboratory Improvement
Amendments of 1988 (CLIA). The State
has established that the quality of
laboratory services required under its
Laboratory licensure program continues
to be equal or more stringent than those
required by the CLIA program.
Washington also has established that it
has a comparable program to monitor
and evaluate compliance with its
laboratory licensure program
requirements. The effect of the
continued exemption from CLIA
requirements is that laboratories will
remain under State, rather than Federal,
regulation, with no discernible
difference in the operations of the
programs. Consequently, we anticipate
that our continued approval of
Washington’s CLIA exemption will not
affect the laboratories or the quality and
availability of services provided.
We have examined the impact of this
notice as required by Executive Order
12866 (September 1993, Regulatory
Planning and Review), the Regulatory
Flexibility Act (RFA) (September 19,
1980, Pub. L. 96–354), section 1102(b) of
the Social Security Act, the Unfunded
Mandates Reform Act of 1995 (Pub. L.
104–4), and Executive Order 13132.
Executive Order 12866 directs
agencies to assess all costs and benefits
of available regulatory alternatives and,
if regulation is necessary, to select
regulatory approaches that maximize
net benefits (including potential
economic, environmental, public health
and safety effects, distributive impacts,
and equity). A regulatory impact
analysis (RIA) must be prepared for
major rules with economically
significant effects ($100 million or more
in any 1 year). This notice does not
reach the economic threshold and thus
is not considered a major rule.
VerDate jul<14>2003
16:04 Apr 28, 2005
Jkt 205001
The RFA requires agencies to analyze
options for regulatory relief of small
businesses. For purposes of the RFA,
small entities include small businesses,
nonprofit organizations, and
government agencies. Most hospitals
and most other providers and suppliers
are small entities, either by nonprofit
status or by having revenues of $6
million to $29 million in any 1 year.
Individuals and States are not included
in the definition of a small entity. We
are not preparing an analysis for the
RFA because we have determined that
this notice will not have a significant
economic impact on a substantial
number of small entities.
In addition, section 1102(b) of the Act
requires us to prepare a regulatory
impact analysis if a notice may have a
significant impact on the operations of
a substantial number of small rural
hospitals. This analysis must conform to
the provisions of section 604 of the
RFA. For purposes of section 1102(b) of
the Act, we define a small rural hospital
as a hospital that is located outside of
a Metropolitan Statistical Area and has
fewer than 100 beds. We are not
preparing an analysis for section 1102(b)
of the Act because we have determined
that this notice will not have a
significant impact on the operations of
a substantial number of small rural
hospitals.
Section 202 of the Unfunded
Mandates Reform Act of 1995 also
requires that agencies assess anticipated
costs and benefits before issuing any
rule that may result in expenditure in
any 1 year by State, local, or tribal
governments, in the aggregate, or by the
private sector, of $110 million. This
notice will have no consequential effect
on the governments mentioned or on the
private sector.
Executive Order 13132 establishes
certain requirements that an agency
must meet when it promulgates a
proposed rule (and subsequent final
rule) that imposes substantial direct
requirement costs on State and local
governments, preempts State law, or
otherwise has Federalism implications.
Since this regulation does not impose
any costs on State or local governments,
the requirements of E.O. 13132 are not
applicable.
In accordance with the provisions of
Executive Order 12866, this regulation
was not reviewed by the Office of
Management and Budget.
Authority: Section 353(p) of the Public
Health Service Act (42 U.S.C. 263a).
(Catalog of Federal Domestic Assistance
Program No. 93.778, Medical Assistance
Program; No. 93.773 Medicare—Hospital
Insurance Program; and No. 93.774,
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
Medicare—Supplementary Medical
Insurance Program)
Dated: April 8, 2005.
Mark B. McClellan,
Administrator, Centers for Medicare &
Medicaid Services.
[FR Doc. 05–8286 Filed 4–22–05; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–5033–N4]
Medicare Program; Meeting of the
Advisory Board on the Demonstration
of a Bundled Case-Mix Adjusted
Payment System for End-Stage Renal
Disease Services—May 24, 2005
Centers for Medicare &
Medicaid Services (CMS),HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This notice announces the
second public meeting of the Advisory
Board on the Demonstration of a
Bundled Case-Mix Adjusted Payment
System for End-Stage Renal Disease
(ESRD) Services. Notice of this meeting
is required by the Federal Advisory
Committee Act (5 U.S.C. App. 2, section
10(a)(1) and (a)(2)). The Advisory Board
will provide advice and
recommendations with respect to the
establishment and operation of the
demonstration mandated by section
623(e) of the Medicare Prescription
Drug, Improvement, and Modernization
Act of 2003.
DATES: The meeting is on May 24, 2005
from 9 a.m. to 5 p.m., eastern standard
time.
Special Accomodations: Persons
attending the meeting, who are hearing
or visually impaired, or have a
condition that requires special
assistance or accommodations, are
asked to notify Pamela Kelly by May 17,
2005 by e-mail at
ESRDAdvisoryBoard@cms.hhs.gov or by
telephone at (410) 786–2461.
ADDRESSES: The meeting will be held at
the Holiday Inn—BWI Airport, 890
Elkridge Landing Rd., Linthicum, MD
21090.
Attendance is limited to the space
available, so seating will be on a first
come, first served basis.
Web site: Up-to-date information on
this meeting is located at https://
www.cms.hhs.gov/faca/esrd.
Hotline: Up-to-date information on
this meeting is located on the CMS
Advisory Committee Hotline at 1 (877)
E:\FR\FM\29APN1.SGM
29APN1
Agencies
[Federal Register Volume 70, Number 82 (Friday, April 29, 2005)]
[Notices]
[Pages 22317-22320]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-8286]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-2207-N]
Medicare, Medicaid, and CLIA Programs; Clinical Laboratory
Improvement Amendments of 1988; Continuance of Exemption of
Laboratories Licensed by the State of Washington
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces that laboratories located in the State
of Washington that possess a valid license under the Medical Test Site
Licensure Law, Chapter 70.42 of the Revised Code of Washington (RCW),
continue to be exempt from the requirements of the Clinical Laboratory
Improvement Amendments of 1988 (CLIA) until April 30, 2007.
DATES: The continuance granted by this notice is effective until April
30, 2007.
FOR FURTHER INFORMATION CONTACT: Sandra Farragut, (410) 786-3531.
SUPPLEMENTARY INFORMATION:
I. Background
Section 353 of the Public Health Service Act (PHS Act), as amended
by the Clinical Laboratory Improvement Amendments of 1988, Pub. L. 100-
578 (CLIA), provides that no laboratory may perform tests on human
specimens unless it has a certificate to perform these tests issued by
the Secretary of the Department of Health and Human Services (HHS).
Under section 1861(s) of the Social Security Act, the Medicare program
will pay for laboratory services only if the laboratory has a CLIA
certificate. Section 1902(a)(9)(C) of the Social Security Act requires
that State Medicaid plans pay only for laboratory services furnished by
CLIA-certified laboratories. Thus, although subject to specified
exemptions, laboratories generally must have a current and valid CLIA
certificate to test human specimens and to be eligible for payment from
the Medicare or Medicaid programs. Regulations implementing section 353
of the PHS Act are contained in 42 CFR part 493.
Section 353(p) of the PHS Act provides for the exemption of
laboratories from CLIA requirements in a State that applies
requirements that are equal to or more stringent than those of CLIA.
Regulations in 42 CFR part 493 subpart E implement section 353(p)
of
[[Page 22318]]
the PHS Act. Sections 493.551 and 493.553 provide that we may exempt
from CLIA requirements, for a period not to exceed 6 years, all State
licensed or approved laboratories in a State if the State Licensure
Program meets specified conditions. Section 493.559 provides that we
will publish a notice in the Federal Register when we grant exemption
to a State Laboratory licensure program. It also provides that the
notice will include the following: the basis for granting the
exemption, a description of how the laboratory requirements are equal
to or more stringent than those of CLIA, and the term of approval, not
to exceed 6 years.
On July 1, 1997 (62 FR 35513), we published a notice in the Federal
Register announcing that the State of Washington had applied for
exemption of its laboratories from CLIA requirements; that the
evaluation of this application demonstrated that all requirements for
exemption were met; and that the Washington State Laboratory licensure
program was granted an approval of CLIA exemption for laboratories in
its program.
II. Requirements for Granting CLIA Exemption
In order to determine whether we should grant or continue an
approval of an existing CLIA exemption to laboratories licensed by a
State, we conduct a detailed and in-depth comparison of State licensure
program and CLIA requirements to determine whether the State program
meets the requirements at Sec. 493.551 and Sec. 493.553. In summary,
the State must--
Have laws in effect that provide for requirements that are
equal to or more stringent than CLIA requirements;
Have a State licensure program that licenses or approves
laboratories that meet State requirements that meet or exceed CLIA
requirements, and, therefore, meet the condition-level requirements of
the CLIA regulations;
Meet the requirements and be approved in accordance with
Sec. 493.555 and Sec. 493.557(b);
Demonstrate that it has enforcement authority and
administrative structures and resources adequate to enforce its
laboratory requirements;
Permit CMS or CMS agents to inspect laboratories within
the State;
Require laboratories within the State to submit to
inspections by CMS or CMS agents as a condition of licensure;
Agree to pay the cost of the validation program
administered by CMS and the cost of the State's pro rata share of the
general overhead to develop and implement CLIA as specified in Sec.
493.645(a), Sec. 493.646(b), and Sec. 493.557(b); and
Take appropriate enforcement action against laboratories
found by CMS or CMS agents not to be in compliance with requirements
comparable to condition-level requirements, as specified in Sec.
493.557(b).
As specified in our regulations at Sec. 493.555 and Sec.
493.557(b), our review of a State laboratory program includes (but is
not necessarily limited to) an evaluation of--
Whether the State's requirements for laboratories are
equal to or more stringent than the CLIA condition-level requirements;
The State's inspection process requirements to determine--
--The comparability of the full inspection and complaint inspection
procedures to those of CMS;
--The State's enforcement procedures for laboratories found to be out
of compliance with its requirements; and
--The ability of the State to provide CMS with electronic data and
reports with the adverse or corrective actions resulting from
proficiency testing (PT) results that constitute unsuccessful
participation in CMS-approved PT programs and with other data we
determine to be necessary for validation review and assessment of the
State's inspection process requirements;
The State's agreement with us to ensure that the agreement
obligates the State to--
--Notify CMS within 30 days of the action taken against any CLIA-exempt
laboratory that has had its licensure or approval withdrawn or revoked
or been in any way sanctioned;
--Notify CMS within 10 days of any deficiency identified in a CLIA-
exempt laboratory in cases when the deficiency poses an immediate
jeopardy to the laboratory's patients or a hazard to the general
public;
--Notify each laboratory licensed by the State within 10 days of CMS'
withdrawal of the exemption;
--Provide CMS with written notification of any changes in its licensure
(or approval) and inspection requirements;
--Disclose to CMS or a CMS agent any laboratory's PT results in
accordance with a State's confidentiality requirements;
--Take the appropriate enforcement action against laboratories found by
CMS not to be in compliance with requirements comparable to CLIA
condition-level requirements and report these enforcement actions to
CMS;
--Notify CMS of all newly licensed laboratories, including changes in
the specialties and subspecialties for which any laboratory performs
testing, within 30 days; and
--Provide CMS, as requested, inspection schedules for validation
purposes.
III. Evaluation of Washington's Request for Continued CLIA Exemption of
Its Laboratories
Washington has applied for continued exemption of its laboratories
from CLIA program requirements.
We evaluated the application to verify Washington's assurance of
continued compliance with the following subparts of part 493: Subpart
H, Participation in Proficiency Testing for Laboratories Performing
Nonwaived Testing; Subpart J, Facility Administration for Nonwaived
Testing; Subpart K, Quality Systems for Nonwaived Testing, Subpart M,
Personnel for Nonwaived Testing; Subpart Q, Inspection; and Subpart R,
Enforcement Procedures.
The Washington State Laboratory Licensure Program was found to
continue to meet the requirements of subparts H, J, K, M, Q, and R.
We also verified the State of Washington's assurance that it
requires the laboratories it licenses to meet the requirements for the
following subparts of part 493 as explained below:
Subpart E--Accreditation by a Private, Nonprofit Accreditation
Organization or Exemption Under an Approved State Laboratory Program
The State of Washington submitted a comparison of its laboratory
licensure requirements with comparable CLIA condition-level
requirements (that is, a crosswalk); a description of its inspection
process; proficiency testing monitoring process; its data management
and analysis system; its investigative and complaint response
procedures; its current list of licensed laboratories; and its policy
regarding announcement and unannouncement of inspections. We have
determined that the State of Washington has complied with the
requirements under subpart E of part 493 and that the requirements of
its laboratory licensure program are equal to the condition-level
requirements in subparts H, J, K, M, Q, and R of part 493.
Subpart H--Participation in Proficiency Testing for Laboratories
Performing Nonwaived Testing
The Washington State program's requirements are equal to the CLIA
[[Page 22319]]
requirements at Sec. 493.801 through Sec. 493.865.
Subpart J--Facility Administration for Nonwaived Testing
The Washington State Program's requirements are equal to the CLIA
requirements at Sec. 493.1100 through Sec. 493.1105.
Subpart K--Quality System for Nonwaived Testing
The Quality Control (QC) requirements of the Washington State
Laboratory Licensure Program have been evaluated against the
requirements of the CLIA regulations. The Washington State Program has
modified its survey process and made revisions to its requirements
encompassing general QC as well as specialty and subspecialty QC
requirements in order to reflect the new QC requirements of the CLIA
regulations. As such, we have determined that the Washington State
Program's requirements are equal to the requirements of the CLIA
regulations.
Subpart M--Personnel for Nonwaived Testing
The Washington State Program requirements are equal to the CLIA
requirements at Sec. 493.1403 through Sec. 493.1495 for laboratories
that perform moderate and high complexity testing.
Subpart Q--Inspections
The Washington State Laboratory Licensure Program requires
laboratories to comply with the inspection requirements of Sec.
493.1773 and Sec. 493.1780 of this subpart, as applicable. Thus, we
have determined that the Washington State Program's requirements are
equal to the requirements of the CLIA regulations.
Subpart R--Enforcement Procedures
The Washington State Program meets the requirements of subpart R to
the extent that subpart R applies to State laboratory licensure
programs. Accordingly, we have determined that the Washington State
Program's enforcement and appeal policies are equal to the requirements
of the CLIA regulations.
IV. Validation Inspections
The Federal validation inspections of CLIA-exempt laboratories, as
specified in Sec. 493.563, were conducted on a representative sample
basis as well as in response to any substantial allegations of
noncompliance (complaint inspections). The outcome of those validation
inspections has been and will continue to be CMS' principal tool for
verifying that the laboratories located in and licensed by the State
are in compliance with CLIA requirements.
Staff in the CMS Regional Office in Seattle, Washington have
conducted validation inspections of a representative sample
(approximately 5 percent) of the laboratories inspected by the
Washington State Office of Laboratory Quality Assurance (LQA). The
validation inspections were primarily of the concurrent type; that is,
CMS surveyors accompanied Washington's inspectors, each inspecting
against his or her agency's respective regulations. Analysis of the
validation data revealed no significant differences between the State
and Federal findings. The validation surveys verified that the
Washington inspection process covers all CLIA conditions applicable to
each laboratory being inspected, and also verified that the State
laboratory licensure requirements meet or exceed CLIA condition-level
requirements. The CMS survey staff found the State inspectors highly
skilled and qualified. The LQA inspected laboratories in timely
fashion, that is, all laboratories were inspected within the required
24-month cycle. All parameters monitored by CMS staff to date indicate
that Washington is meeting all requirements for approval of CLIA
exemption. This Federal monitoring will continue as an on-going
process.
Approval of the CLIA exemption for laboratories located in and
licensed by Washington is subject to removal if we determine that the
outcome of a comparability review or a validation review inspection is
not acceptable, as described under Sec. 493.573 and Sec. 493.575, or
if Washington fails to pay the required fee every 2 years as required
under Sec. 493.646.
V. Laboratory Data
In accordance with Sec. 493.557(b)(8), Washington will continue to
agree to provide us with changes to a laboratory's specialties or
subspecialties based on the State's survey. Washington also will
provide us with changes in a laboratory's certification status, such as
a change from a regular certificate to a certificate of waiver.
VI. Required Administrative Actions
CLIA is a totally user-fee funded program. The registration fee
paid by laboratories is intended to cover the cost of the development
and administration of the program. However, when a State's application
for exemption is approved, we do not charge a fee to laboratories in
the State. The State's share of the costs associated with CLIA must be
collected from the State, as specified in Sec. 493.645.
Washington must pay for the following:
Costs of Federal inspection of laboratories in the State
to verify that Washington's laboratory licensure program requirements
are enforced in an appropriate manner. The average Federal hourly rate
is multiplied by the total hours required to perform Federal validation
surveys within the State.
Costs incurred for Federal investigations and surveys
triggered by complaints that are substantiated. We will bill Washington
on a semiannual basis.
Washington's proportionate share of the costs associated
with establishing, maintaining, and improving the CLIA computer system,
a portion of those services from which Washington received direct
benefit or contributed to the CLIA program in the State. Thus,
Washington is being charged for a portion of CMS' direct and indirect
costs as well as a portion of the costs incurred by the Centers for
Disease Control and Prevention (CDC).
In order to estimate Washington's proportionate share of the
general overhead costs to develop and implement CLIA, we determined the
ratio of laboratories in the State to the total number of laboratories
nationally. Approximately 1.6 percent of the registered laboratories
are in Washington. We determined that 1.6 percent of the applicable CDC
and CMS costs should be borne by Washington.
Washington has agreed to pay us the State's pro rata share of the
overhead costs and anticipated costs of actual validation and complaint
investigation surveys. A final reconciliation for all laboratories and
all expenses will be made. We will reimburse the State for any
overpayment or bill it for any balance.
VII. Approval
CMS grants continued approval of the CLIA exemption for all
laboratory specialties and subspecialties to all laboratories located
in and licensed by the State of Washington effective April 30, 2001 to
April 30, 2007.
The State of Washington applied timely for re-approval, that is, to
continue approval for exemption beyond the period ending April 30,
2001. Review of the application for continued approval, and evaluation
of the outcomes of the validation inspections indicated that continued
approval for 6 more years was in order. The actual publication of the
continued approval was delayed, however, due to the timing of the
publication of changes to the CLIA regulations, and subsequently the
time period necessary
[[Page 22320]]
for the State of Washington to publish corresponding changes to the
Washington State Medical Test Site Rules, which were effective March
19, 2005.
VIII. Collection of Information Requirements
This document does not impose information collection, and
recordkeeping requirements, which are subject to the Paperwork
Reduction Act of 1995 (PRA) (44 U.S.C. 35). Consequently, it need not
be reviewed by the Office of Management and Budget under the authority
of the PRA.
VIX. Regulatory Impact Statement
This notice announces the continuance of the exemption of
laboratories licensed by the State of Washington from the requirements
of the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The
State has established that the quality of laboratory services required
under its Laboratory licensure program continues to be equal or more
stringent than those required by the CLIA program. Washington also has
established that it has a comparable program to monitor and evaluate
compliance with its laboratory licensure program requirements. The
effect of the continued exemption from CLIA requirements is that
laboratories will remain under State, rather than Federal, regulation,
with no discernible difference in the operations of the programs.
Consequently, we anticipate that our continued approval of Washington's
CLIA exemption will not affect the laboratories or the quality and
availability of services provided.
We have examined the impact of this notice as required by Executive
Order 12866 (September 1993, Regulatory Planning and Review), the
Regulatory Flexibility Act (RFA) (September 19, 1980, Pub. L. 96-354),
section 1102(b) of the Social Security Act, the Unfunded Mandates
Reform Act of 1995 (Pub. L. 104-4), and Executive Order 13132.
Executive Order 12866 directs agencies to assess all costs and
benefits of available regulatory alternatives and, if regulation is
necessary, to select regulatory approaches that maximize net benefits
(including potential economic, environmental, public health and safety
effects, distributive impacts, and equity). A regulatory impact
analysis (RIA) must be prepared for major rules with economically
significant effects ($100 million or more in any 1 year). This notice
does not reach the economic threshold and thus is not considered a
major rule.
The RFA requires agencies to analyze options for regulatory relief
of small businesses. For purposes of the RFA, small entities include
small businesses, nonprofit organizations, and government agencies.
Most hospitals and most other providers and suppliers are small
entities, either by nonprofit status or by having revenues of $6
million to $29 million in any 1 year. Individuals and States are not
included in the definition of a small entity. We are not preparing an
analysis for the RFA because we have determined that this notice will
not have a significant economic impact on a substantial number of small
entities.
In addition, section 1102(b) of the Act requires us to prepare a
regulatory impact analysis if a notice may have a significant impact on
the operations of a substantial number of small rural hospitals. This
analysis must conform to the provisions of section 604 of the RFA. For
purposes of section 1102(b) of the Act, we define a small rural
hospital as a hospital that is located outside of a Metropolitan
Statistical Area and has fewer than 100 beds. We are not preparing an
analysis for section 1102(b) of the Act because we have determined that
this notice will not have a significant impact on the operations of a
substantial number of small rural hospitals.
Section 202 of the Unfunded Mandates Reform Act of 1995 also
requires that agencies assess anticipated costs and benefits before
issuing any rule that may result in expenditure in any 1 year by State,
local, or tribal governments, in the aggregate, or by the private
sector, of $110 million. This notice will have no consequential effect
on the governments mentioned or on the private sector.
Executive Order 13132 establishes certain requirements that an
agency must meet when it promulgates a proposed rule (and subsequent
final rule) that imposes substantial direct requirement costs on State
and local governments, preempts State law, or otherwise has Federalism
implications. Since this regulation does not impose any costs on State
or local governments, the requirements of E.O. 13132 are not
applicable.
In accordance with the provisions of Executive Order 12866, this
regulation was not reviewed by the Office of Management and Budget.
Authority: Section 353(p) of the Public Health Service Act (42
U.S.C. 263a).
(Catalog of Federal Domestic Assistance Program No. 93.778, Medical
Assistance Program; No. 93.773 Medicare--Hospital Insurance Program;
and No. 93.774, Medicare--Supplementary Medical Insurance Program)
Dated: April 8, 2005.
Mark B. McClellan,
Administrator, Centers for Medicare & Medicaid Services.
[FR Doc. 05-8286 Filed 4-22-05; 8:45 am]
BILLING CODE 4120-01-P